UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 204

Sortiert nach

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer

Gut, 2018-03, Vol.67 (3), p.497

2018

Volltextzugriff (PDF)

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

British journal of cancer, 2002-05, Vol.86 (10), p.1652-1657

2002

Volltextzugriff (PDF)

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer

Annals of oncology, 2008-07, Vol.19 (7), p.1340-1346

2008

Volltextzugriff (PDF)

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

British journal of cancer, 2014-07, Vol.111 (2), p.318-325

2014

Volltextzugriff (PDF)

Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes

Journal of medicinal chemistry, 2001-10, Vol.44 (22), p.3616-3621

2001

Volltextzugriff (PDF)

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

British journal of cancer, 2012-11, Vol.107 (10), p.1692-1701

2012

Volltextzugriff (PDF)

Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds

Biochemical pharmacology, 2006-02, Vol.71 (4), p.408-415

2006

Volltextzugriff (PDF)

Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma

European journal of cancer (1990), 2004-08, Vol.40 (12), p.1872-1877

2004

Volltextzugriff (PDF)

The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines

European journal of cancer (1990), 2005-07, Vol.41 (11), p.1637-1644

2005

Volltextzugriff (PDF)

Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175

Cancer chemotherapy and pharmacology, 2005-06, Vol.55 (6), p.577-583

2005

Volltextzugriff (PDF)

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

Annals of oncology, 2017-07, Vol.28 (7), p.1678-1679

2017

Volltextzugriff (PDF)

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

British journal of cancer, 2020-06, Vol.122 (12), p.1760-1768

2020

Volltextzugriff (PDF)

Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136

European journal of cancer (1990), 2005-08, Vol.41 (12), p.1811-1818

2005

Volltextzugriff (PDF)

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

British journal of cancer, 2001-12, Vol.85 (12), p.1937-1943

2001

Volltextzugriff (PDF)

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

Journal of clinical oncology, 1992-04, Vol.10 (4), p.520-528

1992

Volltextzugriff (PDF)

Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model

Cancer chemotherapy and pharmacology, 2007-10, Vol.60 (5), p.651-660

2007

Volltextzugriff (PDF)

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

British Journal of Cancer, 1999-11, Vol.81 (5), p.760-768

1999

Volltextzugriff (PDF)

5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

British journal of cancer, 2001-03, Vol.84 (5), p.600-603

2001

Volltextzugriff (PDF)

How many cisplatin administration protocols does your department use?

European journal of cancer care, 2010-01, Vol.19 (1), p.80-90

2010

Volltextzugriff (PDF)

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

British journal of cancer, 2004-02, Vol.90 (4), p.800-804

2004

Volltextzugriff (PDF)

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly

European journal of cancer (1990), 2000-12, Vol.36 (18), p.2353-2359

2000

Volltextzugriff (PDF)

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

JNCI : Journal of the National Cancer Institute, 1993-04, Vol.85 (8), p.611-621

1993

Volltextzugriff (PDF)

ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136

The pharmacogenomics journal, 2008-08, Vol.8 (4), p.289-296

2008

Volltextzugriff (PDF)

Population pharmacokinetics of gentamicin in patients with cancer

British journal of clinical pharmacology, 1998-09, Vol.46 (3), p.229-236

1998

Volltextzugriff (PDF)

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

Journal of clinical oncology, 1995-09, Vol.13 (9), p.2174-2186

1995

Volltextzugriff (PDF)

1 – 25 von 204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(201)
Mit Volltextzugriff
(189)

Publikationsform

Artikel
(203)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds

Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma

The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines

Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

How many cisplatin administration protocols does your department use?

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136

Population pharmacokinetics of gentamicin in patients with cancer

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

Suchergebnisse filtern